Gb002, Inc.
Clinical trials sponsored by Gb002, Inc., explained in plain language.
-
Inhaled hope for scarred lungs: trial tests new therapy
Disease control TerminatedThis study is testing an inhaled medication called seralutinib for people with high blood pressure in the lungs caused by scarring from another lung disease. The main goal is to see if the drug can help people walk farther in six minutes after 24 weeks of treatment. The trial wil…
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Breathing easier: long-term hope for PAH patients
Disease control OngoingThis study continues testing an inhaled medication called seralutinib for people with pulmonary arterial hypertension (PAH) who completed earlier trials. It aims to understand the long-term safety and effectiveness of this treatment. The study will monitor patients' ability to wa…
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC